Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier, Ariane Morel, Nadia Anceriz, et al.
Cell (2019) Vol. 177, Iss. 7, pp. 1701-1713.e16
Open Access | Times Cited: 359

Showing 1-25 of 359 citing articles:

Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
Nature reviews. Cancer (2021) Vol. 21, Iss. 5, pp. 298-312
Closed Access | Times Cited: 968
NK cells for cancer immunotherapy
Noriko Shimasaki, Amit Jain, Dario Campana
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 3, pp. 200-218
Closed Access | Times Cited: 959
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers, Jeffrey S. Miller
Nature Reviews Clinical Oncology (2020) Vol. 18, Iss. 2, pp. 85-100
Open Access | Times Cited: 908
Harnessing innate immunity in cancer therapy
Olivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature (2019) Vol. 574, Iss. 7776, pp. 45-56
Closed Access | Times Cited: 751
NK cell-based cancer immunotherapy: from basic biology to clinical development
Sizhe Liu, Vasiliy Galat, Yekaterina Galat, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 491
Natural killer cells in antitumour adoptive cell immunotherapy
Tamara Laskowski, Alexander Biederstädt, Katayoun Rezvani
Nature reviews. Cancer (2022) Vol. 22, Iss. 10, pp. 557-575
Open Access | Times Cited: 471
The cancer–natural killer cell immunity cycle
Nicholas D. Huntington, Joseph Cursons, Jai Rautela
Nature reviews. Cancer (2020) Vol. 20, Iss. 8, pp. 437-454
Closed Access | Times Cited: 442
Tumor-Infiltrating Natural Killer Cells
Beatriz Cózar, Marco Greppi, Sabrina Carpentier, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 34-44
Open Access | Times Cited: 346
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Natalie K. Wolf, Djem Kissiov, David H. Raulet
Nature reviews. Immunology (2022) Vol. 23, Iss. 2, pp. 90-105
Closed Access | Times Cited: 299
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall, Pascale André, Amir Horowitz, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 235
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Benjamin Ruf, Bernd Heinrich, Tim F. Greten
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 112-127
Open Access | Times Cited: 233
Multispecific drugs herald a new era of biopharmaceutical innovation
Raymond J. Deshaies
Nature (2020) Vol. 580, Iss. 7803, pp. 329-338
Closed Access | Times Cited: 224
NK cells and ILCs in tumor immunotherapy
Simona Sivori, Daniela Pende, Linda Quatrini, et al.
Molecular Aspects of Medicine (2020) Vol. 80, pp. 100870-100870
Open Access | Times Cited: 191
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins, S. Khan, Maria M. Park, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 9, pp. 3499-3510
Open Access | Times Cited: 183
The Role of Natural Killer Cells in Autoimmune Diseases
Umut Can Küçüksezer, Esin Aktaş Çetin, Fehim Esen, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 177
The landscape of bispecific T cell engager in cancer treatment
Yingtang Zhou, Ming‐Guo Liu, Fei Ren, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 156
SnapShot: Natural Killer Cells
Adeline Crinier, Émilie Narni-Mancinelli, Sophie Ugolini, et al.
Cell (2020) Vol. 180, Iss. 6, pp. 1280-1280.e1
Open Access | Times Cited: 151
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Guanghe Ran, Yu qing Lin, Lei Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 147
METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells
Hao Song, Jiaxi Song, Ming Cheng, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 143
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
Tao Shi, Xueru Song, Yue Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 140
Designing antibodies as therapeutics
Paul J. Carter, Arvind Rajpal
Cell (2022) Vol. 185, Iss. 15, pp. 2789-2805
Open Access | Times Cited: 137
Natural killer cell therapies
Éric Vivier, Lucas Rebuffet, Émilie Narni-Mancinelli, et al.
Nature (2024) Vol. 626, Iss. 8000, pp. 727-736
Closed Access | Times Cited: 136
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 559-577
Open Access | Times Cited: 135
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 119
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
Olivier Demaria, Laurent Gauthier, Guilhaume Debroas, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 8, pp. 1934-1942
Closed Access | Times Cited: 115
Page 1 - Next Page

Scroll to top